Price$6.58-0.08 (-1.20%)
01:30 PM07:45 PM
News · 26 weeks45-45%
2026-01-182026-07-12
Mix2390d
- Insider12(52%)
- SEC Filings6(26%)
- Earnings3(13%)
- Other1(4%)
- Leadership1(4%)
Latest news
25 items- PRInogen to Report Second Quarter 2026 Financial Results on August 6, 2026Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report second quarter 2026 financial results after the market closes on Thursday, August 6, 2026. On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET.Individuals interested in listening to the conference call may do so by dialing:U.S. domestic callers (877) 841-3961Non-U.S. callers (201) 689-8589Please reference Inogen to join the call. A live audio webcast and archived recording of the conference call will be available to all interested parties through the News / Events page on the Inogen Investor
- INSIDERSEC Form 4 filed by EVP, COO Reding Andrew P.4 - Inogen Inc (0001294133) (Issuer)
- INSIDERSEC Form 3 filed by new insider Reding Andrew P.3 - Inogen Inc (0001294133) (Issuer)
- INSIDEREVP Entrprs Enblmnt, Ch HR Off Yi Boyer Jennifer M sold $72,146 worth of shares (10,938 units at $6.60) as part of a pre-agreed trading plan, decreasing direct ownership by 68% to 5,039 units (SEC Form 4)4 - Inogen Inc (0001294133) (Issuer)
- SECInogen Inc filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Inogen Inc (0001294133) (Filer)
- PRInogen Announces the Appointment of Andy Reding as Chief Operating OfficerNewly created role strengthens leadership structure to support Inogen’s global commercial and operational execution Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Andy Reding to the newly created role of Chief Operating Officer, effective Monday, July 6, 2026. Mr. Reding will be responsible for driving revenue and operational performance, aligning cross-functional priorities, and helping ensure Inogen’s strategy is translated into efficient and measurable outcomes. "As we continue to diversify Inogen’s business through new product launches and geographic expansion, we
- SECSEC Form S-8 filed by Inogen IncS-8 - Inogen Inc (0001294133) (Filer)
- INSIDERDirector Sahney Mira Kirti was granted 28,081 shares, increasing direct ownership by 71% to 67,805 units (SEC Form 4)4 - Inogen Inc (0001294133) (Issuer)
- INSIDERDirector Jamali Vafa was granted 28,081 shares, increasing direct ownership by 187% to 43,081 units (SEC Form 4)4 - Inogen Inc (0001294133) (Issuer)
- INSIDERDirector Boehnlein Glenn S was granted 28,081 shares, increasing direct ownership by 37% to 104,966 units (SEC Form 4)4 - Inogen Inc (0001294133) (Issuer)
- INSIDERDirector Rider Heather D. was granted 28,081 shares, increasing direct ownership by 32% to 116,282 units (SEC Form 4)4 - Inogen Inc (0001294133) (Issuer)
- INSIDERDirector Mora Elizabeth was granted 28,081 shares, increasing direct ownership by 35% to 107,261 units (SEC Form 4)4 - Inogen Inc (0001294133) (Issuer)
- INSIDERDirector Ladone Mary Kay was granted 28,081 shares, increasing direct ownership by 37% to 104,966 units (SEC Form 4)4 - Inogen Inc (0001294133) (Issuer)
- INSIDERDirector King Kevin M was granted 28,081 shares, increasing direct ownership by 37% to 104,966 units (SEC Form 4)4 - Inogen Inc (0001294133) (Issuer)
- INSIDERNew insider Jamali Vafa claimed ownership of 15,000 shares (SEC Form 3)3 - Inogen Inc (0001294133) (Issuer)
- INSIDEREVP Entrprs Enblmnt, Ch HR Off Yi Boyer Jennifer M sold $70,313 worth of shares (10,770 units at $6.53) as part of a pre-agreed trading plan, decreasing direct ownership by 40% to 15,977 units (SEC Form 4)4 - Inogen Inc (0001294133) (Issuer)
- SECSEC Form SD filed by Inogen IncSD - Inogen Inc (0001294133) (Filer)
- SECSEC Form 10-Q filed by Inogen Inc10-Q - Inogen Inc (0001294133) (Filer)
- SECInogen Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Inogen Inc (0001294133) (Filer)
- PRInogen Announces First Quarter 2026 Financial ResultsReported first quarter year-over-year revenue growth of 3.4% Company reiterates full-year 2026 guidance Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended March 31, 2026 and reiterated its full-year guidance. "Our first quarter revenue exceeded our outlook with revenue growth of 3.4% as we continue to execute on our clinical and strategic priorities that we believe will position us for growth acceleration and improved profitability in the second half of the year and beyond," said Kevin Smith, Inogen's Chief Executive Officer. "Our progress reflects the
- SECSEC Form S-8 filed by Inogen IncS-8 - Inogen Inc (0001294133) (Filer)
- SECSEC Form DEF 14A filed by Inogen IncDEF 14A - Inogen Inc (0001294133) (Filer)
- PRInogen to Report First Quarter 2026 Financial Results on May 7, 2026Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report first quarter 2026 financial results after the market closes on Thursday, May 7, 2026. On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET. Individuals interested in listening to the conference call may do so by dialing: U.S. domestic callers (877) 841-3961 Non-U.S. callers (201) 689-8589 Please reference Inogen to join the call. A live audio webcast and archived recording of the conference call will be available to all interested parties through the News / Events page on the Inogen I
- SECSEC Form PRE 14A filed by Inogen IncPRE 14A - Inogen Inc (0001294133) (Filer)
- INSIDERSEC Form 4 filed by Richardson Jason Andrew4 - Inogen Inc (0001294133) (Issuer)
INGN FAQ
7 questionsWhat does Inogen Inc do?
Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Inogen Tidal Assist Ventilators, as well as...Where does INGN stock trade?
Inogen Inc (INGN) is listed on NASDAQ.What sector and industry is INGN in?
Inogen Inc operates in the Health Care sector, Industrial Specialties industry.When did Inogen Inc go public?
Inogen Inc (INGN) completed its IPO in 2014.What are analysts saying about INGN?
Inogen Inc has had 8 recent analyst actions on file. The most recent action was from B. Riley Securities: Buy with a $1400.00 price target on 2025-06-16.What companies are similar to INGN?
Notable peers in the same industry include ISRG (Intuitive Surgical Inc.), EW (Edwards Lifesciences Corporation), STE (STERIS plc (Ireland)), ZBH (Zimmer Biomet Holdings Inc.), MAS (Masco Corporation). Compare INGN side-by-side with any of them on Quantisnow.How can I track INGN on Quantisnow?
Quantisnow aggregates Inogen Inc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow INGN to receive live email and push alerts on every new disclosure.